$TCRX

TScan Therapeutics granted retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski. The awards include cash and equity, with vesting tied to milestones and continued service. MacBeath received $822,000 in cash and 2.4 million RSUs, while Zdraveski received $416,000 and 1.05 million RSUs.

TScan Therapeutics (TCRX) approved a retention program on September 8, 2026, granting CEO Gavin MacBeath $822,000 in cash and 2.4M RSUs, and Chief Legal Officer Zoran Zdraveski $416,000 and 1.05M RSUs. Payments are tied to clinical and financing milestones, with partial cash payouts scheduled for November 2026 and February 2027.

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the Compensation Committee of the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

TScan Therapeutics (TCRX) announced a reorganization to focus on its in vivo solid tumor pipeline, reducing its workforce by 75%. The company paused enrollment in its Phase 3 ALLOHA-2 study due to funding constraints. TScan plans to release preclinical data in Q1 2027 and initiate Phase 1 development in Q4 2027. Shares were down 36.95% to 42 cents at the time of publication.

Wedbush downgraded Tscan Therapeutics (TCRX) to Neutral, lowering its price target to $1.00 from $5.00 due to a strategic shift. The company paused its Phase 3 ALLOHA-2 study and refocused on preclinical programs, reducing staff by 75%. Despite cash burn concerns, InvestingPro suggests the stock may be undervalued. H.C. Wainwright reiterated a Buy rating with a $7.00 target, citing positive trial data.

TScan Therapeutics (TCRX) reported that two in vivo TCR therapies for solid tumors have entered IND-enabling stages, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The company's heme malignancy and autoimmune programs are paused pending partnerships. TCRX's financial runway extends to Q4 2027, according to a study update.

TScan Therapeutics (TCRX) shares fell 28.8% after announcing a strategic reorganization, including a 75% workforce reduction, pausing its Phase 3 ALLOHA-2 trial due to insufficient capital, and redirecting resources to solid tumor candidates. The company expects $55M in cost savings by 2027 and has a cash runway into Q4 2027. It is seeking collaboration partners for paused programs.

TScan Therapeutics (TCRX) is cutting 75% of its workforce and refocusing on solid tumor programs. The company expects $55M in savings through 2027 and plans to advance two product candidates. It paused enrollment in a Phase 3 trial due to insufficient capital and is seeking partners for its hematologic malignancies and autoimmune programs.

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated dat